Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is pathologic complete remission a useful measure of response to novel therapies in neoadjuvant trials?

Nature Clinical Practice Oncology volume 3, pages 126–127 (2006)Cite this article

boxed-textGreen MC et al. (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23: 5983–5992

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wolmark N et al. (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96–102

    Article  Google Scholar 

  2. Bear HD et al. (2004) A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preoperative AC followed by preoperative docetaxel (T) and to preoperative AC followed by postoperative T in patients with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res Treat 88 (Suppl 1): aS26

    Google Scholar 

  3. Ring AE et al. (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 91: 2012–2017

    Article  Google Scholar 

  4. Seidman AD et al. (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22 (Suppl 14): aS512

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. research fellow, Department of Medicine at the Royal Marsden Hospital, London, UK

    Alexandra Leary

  2. Professor of Cancer Medicine in the Department of Medicine at the Royal Marsden Hospital, London, UK

    Ian Smith

Authors
  1. Alexandra Leary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian Smith.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leary, A., Smith, I. Is pathologic complete remission a useful measure of response to novel therapies in neoadjuvant trials?. Nat Rev Clin Oncol 3, 126–127 (2006). https://doi.org/10.1038/ncponc0447

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0447

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing